Christopher Paul Day

Christopher Paul Day's AcademicInfluence.com Rankings

Philosophy

#4223

World Rank

#6666

Historical Rank

Logic

#1728

World Rank

#2563

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Christopher Paul Day's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is Christopher Paul Day Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christopher Paul Day's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Steatohepatitis: a tale of two "hits"? (1998) (3951)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) (2381)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016) (1859)
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. (2010) (1381)
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (2013) (1332)
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications (1999) (1264)
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin (2009) (956)
The natural history of nonalcoholic fatty liver: A follow‐up study (1995) (939)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) (881)
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015) (819)
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers (2007) (701)
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (2010) (689)
Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease (2010) (573)
EASL clinical practical guidelines: management of alcoholic liver disease. (2012) (570)
Non-alcoholic fatty liver disease: the mist gradually clears. (2008) (565)
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. (2004) (476)
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) (468)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. (2012) (464)
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver (1995) (456)
Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss (2011) (440)
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) (426)
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. (2011) (421)
From fat to inflammation. (2006) (420)
Pathogenesis of steatohepatitis. (2002) (419)
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. (2013) (417)
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. (2016) (406)
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study (2011) (403)
Hepatic steatosis: Innocent bystander or guilty party? (1998) (395)
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. (2014) (392)
Nonalcoholic fatty liver disease (2015) (374)
Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. (1998) (373)
Elevated endotoxin levels in non-alcoholic fatty liver disease (2010) (333)
From NAFLD in clinical practice to answers from guidelines. (2013) (332)
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score (2005) (326)
Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. (2007) (319)
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease (2010) (296)
The genetics of NAFLD (2013) (295)
Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis (1997) (291)
Standardization of nomenclature and causality assessment in drug‐induced liver injury: Summary of a clinical research workshop (2010) (288)
Non-alcoholic steatohepatitis: another disease of affluence (1999) (281)
Prednisolone or pentoxifylline for alcoholic hepatitis. (2015) (277)
QT prolongation and sudden cardiac death in patients with alcoholic liver disease (1993) (250)
Benefits of lifestyle modification in NAFLD (2007) (240)
NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men (2008) (212)
Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C (1998) (209)
Non-Alcoholic Fatty Liver Disease in Older People (2009) (208)
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity (2004) (203)
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. (2020) (202)
Treatment of Non-Alcoholic Fatty Liver Disease (2014) (199)
Non-alcoholic steatohepatitis: from cell biology to clinical practice. (2006) (198)
Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis (2005) (197)
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients (2007) (192)
Alcoholic liver disease: new insights into mechanisms and preventative strategies. (2001) (189)
S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. (2012) (189)
Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? (2002) (187)
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. (2008) (185)
Polymerase γ Gene POLG determines the risk of sodium valproate‐induced liver toxicity (2010) (184)
Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. (2007) (182)
Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance (2008) (180)
Candidate gene case-control association studies: advantages and potential pitfalls. (2001) (180)
The natural history of histologically proved drug induced liver disease (1999) (178)
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. (2016) (175)
How big a problem is non-alcoholic fatty liver disease? (2011) (173)
Genes or environment to determine alcoholic liver disease and non‐alcoholic fatty liver disease (2006) (170)
Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease (2000) (164)
A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. (2007) (163)
Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. (2015) (160)
Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease (2016) (159)
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. (2017) (157)
Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD (2012) (156)
Non-alcoholic fatty liver disease: current concepts and management strategies. (2006) (153)
Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. (2007) (153)
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. (2012) (152)
Pathogenesis of alcohol‐induced liver disease: Classical concepts and recent advances (2011) (152)
Management strategies in alcoholic liver disease (2007) (150)
Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol‐related end‐organ damage (1991) (149)
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease (2010) (149)
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. (2015) (148)
Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. (2007) (148)
Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. (2002) (140)
Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial (2017) (140)
Genetic association studies in drug-induced liver injury. (2009) (135)
The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2 (2015) (134)
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. (2010) (133)
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease (2008) (129)
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. (2000) (128)
Accuracy of hepatic adverse drug reaction reporting in one English health region (1999) (126)
The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids (2007) (125)
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD (2016) (124)
Non-alcoholic fatty liver disease: a massive problem. (2011) (119)
Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance (1998) (119)
Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. (2012) (118)
PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease (2015) (117)
Genetics of alcoholic and nonalcoholic fatty liver disease. (2011) (114)
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis (2020) (112)
The management of alcoholic liver disease. (2003) (111)
Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease (2013) (108)
Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. (2000) (105)
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. (2013) (104)
Transplantation for alcoholic liver disease. (2002) (101)
Association of the tumour necrosis factor α −308 but not the interleukin 10 −627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis (2001) (101)
The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. (1998) (94)
379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease (2014) (93)
Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls (2014) (92)
Detection and characterization of novel polymorphisms in the CYP2E1 gene. (1998) (91)
Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. (2010) (90)
Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease (2004) (89)
Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? (2013) (86)
Other clinical studyThe natural history of nonalcoholic fatty liver: A follow-up study (1995) (84)
Genetic and Environmental Susceptibility to Non-Alcoholic Fatty Liver Disease (2010) (84)
Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease (1998) (83)
Nonalcoholic fatty liver disease: new treatments (2015) (83)
The biochemistry of alcohol-induced fatty liver. (1994) (82)
A Methodological Approach to Tracing Cell Lineage in Human Epithelial Tissues (2009) (81)
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. (2011) (80)
Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. (2007) (78)
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease (2009) (77)
Gut Microbiota and Lifestyle Interventions in NAFLD (2016) (76)
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. (2019) (75)
Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease (2009) (72)
Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. (2014) (71)
Genes and nonalcoholic fatty liver disease (2008) (69)
Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis (2012) (69)
Pain as a complication of use of opiate antagonists for symptom control in cholestasis. (2003) (67)
Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial (2013) (65)
Genetic modifiers of non-alcoholic fatty liver disease progression. (2011) (65)
Tumour necrosis factor-a promoter polymorphisms in primary biliary cirrhosis (1999) (64)
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease (2011) (63)
Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. (2002) (63)
TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? (2015) (61)
A role for the pregnane X receptor in flucloxacillin‐induced liver injury (2010) (61)
Who Gets Alcoholic Liver Disease: Nature or Nurture? (2000) (60)
Glucokinase links Krüppel‐like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease (2012) (60)
TM 6 SF 2 rs 58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease (2014) (59)
Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease (2003) (59)
Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes (2018) (59)
Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease (2014) (59)
Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. (2010) (56)
Genetic predisposition to alcoholic liver disease. (1992) (55)
The potential role of genes in nonalcoholic fatty liver disease. (2004) (55)
Warfarin dose requirement and CYP2C9 polymorphisms (1999) (54)
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group (2014) (52)
Role of Polymorphisms in the Interleukin-10 Gene in Determining Disease Susceptibility and Phenotype in Inflamatory Bowel Disease (2001) (46)
Genetic association studies in drug-induced liver injury (2012) (45)
Functional Impairment in Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease Is Significant and Persists over 3 Years of Follow-Up (2013) (45)
Inhibition of rat hepatocyte proliferation by transforming growth factor β and glucagon is associated with inhibition of ERK2 and p70 S6 kinase (1999) (45)
Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. (2014) (43)
127 HOMOZYGOSITY FOR THE PNPLA3/ADIPONUTRIN I148M POLYMORPHISM INFLUENCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2010) (42)
The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. (2020) (42)
Genetics of Alcoholic Liver Disease (2015) (42)
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. (2010) (41)
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. (2014) (40)
Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control (2015) (40)
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis (2017) (39)
The activity of the metabolic form of hepatic phosphatidate phosphohydrolase correlates with the severity of alcoholic fatty liver in human beings (1993) (38)
Apoptosis in alcoholic hepatitis: a novel therapeutic target? (2001) (36)
Nash-related liver failure: one hit too many? (2002) (36)
The degree of hepatic steatosis associates with impaired cardiac and autonomic function. (2019) (35)
White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers (2013) (33)
Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. (2009) (33)
Alcohol dehydrogenase polymorphisms and predisposition to alcoholic cirrhosis (1993) (33)
Adverse physical effects of alcohol misuse (2008) (32)
The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. (2015) (32)
Physical evidence for the presence of two forms of phosphatidate phosphohydrolase in rat liver. (1992) (32)
Patatin‐like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease (2010) (31)
Liver under Constant Attack — From Fat to Viruses (2009) (31)
Clinical but not histological factors predict long‐term prognosis in patients with histologically advanced non‐decompensated alcoholic liver disease (2014) (30)
Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation (2005) (29)
No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. (1998) (27)
Brief Report: Genetics of Alcoholic Cirrhosis—GenomALC Multinational Study (2015) (27)
The effect of gastritis on human gastric alcohol dehydrogenase activity and ethanol metabolism (1995) (27)
Clinical Spectrum and Therapy of Non-Alcoholic Steatohepatitis (2012) (26)
CYP2C9 polymorphism and warfarin dose requirements. (2002) (26)
Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease. (2013) (25)
Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. (1999) (24)
Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors (2020) (24)
Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. (2021) (24)
Treatment of alcoholic liver disease (2007) (24)
The role of phosphatidic acid in platelet‐derived growth factor–induced proliferation of rat hepatic stellate cells (2000) (24)
Is necroinflammation a prerequisite for fibrogenesis? (1996) (23)
Valine‐alanine manganese superoxide dismutase polymorphism is not associated with alcohol‐induced oxidative stress or liver fibrosis (2002) (21)
A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis (2002) (21)
Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. (2015) (20)
Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism. (1995) (20)
Polymorphisms in Immunoregulatory Genes (2002) (19)
Human liver stem cells originate from the canals of hering (2009) (18)
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. (2021) (18)
A disease of emerging identity and importance (1998) (18)
Risk of all-cause and cardiovascular mortality in patients with chronic liver disease (2010) (17)
Relationship between the inhibition of phosphatidic acid phosphohydrolase-1 by oleate and oleoyl-CoA ester and its apparent translocation. (2005) (17)
Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. (2020) (16)
Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. (2011) (16)
Non-Alcoholic Fatty Liver Disease: A Practical Guide (2013) (16)
7 The inheritance of alcoholic liver disease (1998) (16)
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease (2011) (16)
How to Diagnose Nonalcoholic Fatty Liver Disease (2016) (15)
Genetic studies to identify hepatic fibrosis genes and SNPs in human populations. (2005) (15)
Comparison of the Glasgow Alcoholic Hepatitis Score and the ABIC Score for the Assessment of Alcoholic Hepatitis (2010) (14)
CD14 promoter polymorphism associated with risk of NASH (2002) (14)
Alcohol and the liver (2002) (14)
Alcoholic liver disease: dose and threshold—new thoughts on an old topic (1997) (14)
No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. (2008) (13)
Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. (2018) (13)
No evidence for involvement of type 1 collagen structural genes in 'genetic predisposition' to alcoholic cirrhosis. (1992) (12)
Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans (2016) (12)
Liver Diseases in 2013: Advances in Pathogenesis and Treatment: Falk Symposium 191, London, October 2013 (2014) (12)
Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease (2020) (12)
104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE (2013) (12)
Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth factor and extracellular nucleotides. (2006) (12)
Polymorphisms in immunoregulatory genes: towards individualized immunosuppressive therapy? (2002) (12)
Orthostatic intolerance is common in chronic disease--a clinical cohort study. (2014) (11)
British Association for the Study of the Liver (1991) (11)
Genetic evidence for a role for gut flora in the pathogenesis of NASH in humans (2006) (10)
Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor (2008) (10)
Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers (2017) (10)
Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease (2003) (10)
Recombinant lysosomal acid lipase normalizes liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesteryl ester storage disease (2011) (9)
Current and future therapeutic strategies in NAFLD. (2010) (9)
Regulation of phosphatidic acid phosphohydrolase 1 by fatty acids (2002) (9)
Systems Genetics of Hepatic Metabolome Reveals Octopamine as a Target for Non-Alcoholic Fatty Liver Disease Treatment (2019) (9)
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance (2021) (9)
The inheritance of alcoholic liver disease. (1998) (9)
Falls and Fall-Related Injury Are Common in Older People with Chronic Liver Disease (2012) (9)
Genetic variants of hepatic transporters and susceptibility to drug induced liver injury (2008) (9)
Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome (2009) (8)
European liver fibrosis (ELF) panel of serum markers can predict clinical outcome in a cohort of patients from England with mixed aetiology chronic liver disease (2007) (8)
Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD (2012) (8)
A coffee with your brandy, Sir? (2007) (8)
The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic NAFLD: Consistent evidence from case-control and intra-familial allelic association studies (2007) (7)
No association between functional SNPS in the endotoxin receptors CD14 and TLR4 and alcoholic liver disease Is endotoxin important in the pathogenesis of ALD in humans (2001) (7)
Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol. (2016) (7)
Transforming growth factor beta increases the activity of phosphatidate phosphohydrolase-1 in rat hepatocytes. (1997) (7)
900 RECOMBINANT LYSOSOMAL ACID LIPASE NORMALIZES LIVER WEIGHT, TRANSAMINASES AND HISTOPATHOLOGICAL ABNORMALITIES IN AN MODEL OF CHOLESTERYL ESTER STORAGE DISEASE (2011) (7)
Sugar sweetened beverages and fatty liver disease: Rising concern and call to action. (2015) (7)
TM6SF2 rs58542926 influences hepatic fibrosis (2015) (7)
Erratum: 'Investigations of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end- organ damage' (Hepatology (1991) 14 (798-801)) (1992) (7)
Plasma membrane form of phosphatidate phosphohydrolase: a possible role in signal transduction during liver fibrogenesis. (1993) (6)
The genetic basis for non-alcoholic and alcoholic steatohepatitis. (2001) (6)
1275 CARRIAGE OF PNPLA3 I148M IS ASSOCIATED WITH AN INCREASED RISK OF NON-ALCOHOLIC FATTY LIVER DIESEASE ASSOCIATED HEPATOCELLULAR CARCINOMA (2013) (6)
Nonalcoholic Fatty Liver Disease (2015) (6)
A lipid to treat non-alcoholic fatty liver disease - the dawn of 'lipo-rehabilitation'? (2012) (6)
Susceptibility to drug induced liver injury determined by HLA class II genotype (2008) (6)
WARFARIN DOSE REQUIREMENT AND CYP2C9 POLYMORPHISMS. AUTHORS' REPLY (1999) (5)
Cognitive impairment in non-cirrhotic chronic liver disease is unrelated to liver disease severity but associated with ineffective baroreflex function (2011) (5)
Genetic evidence supporting the two-hit model of NASH pathogenesis (2002) (5)
Pure alcoholic fatty liver and progression to cirrhosis or fibrosis (1995) (5)
Promoter polymorphisms of interleukin-10 (IL-10) and interleukin-4 (IL-4) predict the risk of diclofenac-induced hepatotoxicity (2000) (5)
Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis (2001) (4)
Mitochondrial DNA does not contribute to the heritability of non-alcoholic fatty liver disease. (2011) (4)
844 RESISTANCE EXERCISE IMPROVES LIVER LIPID, FAT OXIDATION AND GLUCOSE CONTROL IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE INDEPENDENT OF WEIGHT LOSS (2011) (4)
603 Correlation between anti-cyp2E1 titre and lymphocyte infiltration in ALD — an autoimmune disease in some patients? (2004) (4)
Who gets alcoholic liver disease: nature or nurture? (extended abstract). (2003) (4)
The genetic basis of hepatocellular cancer (2006) (4)
26 – Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease (2018) (4)
ALCOHOLISM | Effects on Nutritional Status (1998) (3)
12. ALCOHOLIC LIVER DISEASE (2004) (3)
Fatty liver disease is associated with both endotoxaemia and sub-clinical inflammation which is further aggravated by diabetes (2005) (3)
Common POLG Genetic Variants Increase the Risk of Sodium Valproate Induced Liver Injury and Failure (2009) (3)
Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease (2013) (3)
Predictive Value of Cytokine Polymorphisms for Liver Disease (2002) (3)
Prevalence of auto-antibodies against cytochrome P4502E1 in alcoholic liver disease (2001) (3)
Substantial variability of the diagnostic accuracy of serum fibrosis markers across multiple cohorts of nash patients in various centers : the case for the negative predictive value (2015) (3)
Risk factors for alcohol‐related liver disease (2015) (2)
TM6SF2 as a genetic risk factor for fibrosis (2015) (2)
Chapter 29 – Alcoholic Liver Disease (2006) (2)
A randomised controlled trial of calcineurin inhibitor (CNI) replacement with mycophenolate mofetil and steroids in liver transplant patients with renal dysfunction (2004) (2)
Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort"☆ (J Hepatol [2020] 505-515). (2021) (2)
Nash is A Genetically Determined Disease (2007) (2)
High intensity intermittent training improves cardiac function and reduces liver fat in adults with Type 2 diabetes: an MRI/S study (2015) (2)
Researchendotoxin levels in non-alcoholic fatty liver disease (2010) (2)
Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease (2002) (2)
Genetic variation in TM 6 SF 2 and the risk of nonalcoholic fatty liver disease and histological disease severity " by Sookoian (2014) (2)
An algorithm combining direct and indirect liver fibrosis tests enhances diagnostic performance for the detection of advanced fibrosis (F3-4) in NAFLD minimising the need for liver biopsy (2012) (2)
Corrigendum: PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease (2015) (2)
Cognitive Symptoms and Prevalent in Non-Alcoholic Fatty Liver Disease (NAFLD) and Unrelated to the Severity of Liver Disease (2009) (2)
Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis (1999) (2)
PTH-090 Natural History Of Nafld: A Study Of 108 Patients With Paired Liver Biopsies (2014) (2)
Increased susceptibility to alcoholic liver disease in females is not due to either higher blood alcohol concentrations or lower first pass metabolism (1995) (2)
HFE AND ALCOHOLIC LIVER DISEASE. AUTHOR'S REPLY (1999) (1)
Association of udp-glucuronosyltransferase (UGT) 2B7 genotype with diclofenac-induced hepatotoxicity (2002) (1)
Can genetic influence in non‐alcoholic fatty liver disease be ignored? (2016) (1)
80 The glasgow alcoholic hepatitis score identifies patients likely to benefit from corticosteroids (2004) (1)
Appreciation of the benefits of exercise programmes in non-alcoholic liver disease: implications of fatigue and impact upon activities of daily living (2008) (1)
Steatosis and Inflammation are Together Associated with Fibrosis Progression in Patients with NASH (2009) (1)
Obstructive sleep apnoea is common in adults with biopsy-proven non-alcoholic fatty liver disease. (2015) (1)
Poster sessionsPrevalence of auto-antibodies against cytochrome P4502E1 in alcoholic liver disease (2001) (1)
Intravenous bisphosphonate pre liver transplant prevents osteoporotic vertebral collapse (1996) (1)
EditorialNash-related liver failure: one hit too many? (2002) (1)
Liver disorder and the HFE locus. (2001) (1)
PWE-285 Clinical but not histological factors predict long-term prognosis in patients with biopsy proven advanced alcoholic liver disease (2012) (1)
72 MAPPING EXPRESSION QUANTITATIVE TRAITS LOCI (eQTL) FOR PNPLA3 GENE IDENTIFIES ADDITIONAL SNPS ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) INDEPENDENT OF rs738409 (2013) (1)
Erratum: PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease (Am J Gastroenterol 110:846-856(2015) DOI: 10.1038/ajg.2015.137) (2015) (1)
Alpha-1-antitrypsin genotype — A risk factor for alcoholic cirrhosis? (1991) (1)
Resistance exercise improves liver fat and glucose control in people with non-alcoholic fatty liver disease (2011) (1)
Stimulation of phosphatidate phosphohydrolase by T6F$beta; in hepatocytes: A possible mechanism for the antiproliferative effects? (1993) (1)
Relevance of PXR to Flucloxacillin-induced Liver Injury (2008) (1)
POLG determines the risk of sodium valproate induced liver toxicity (2013) (1)
A 'loss-of-function' mutation in TIRAP, the gene encoding the Toll-like receptor adapter molecule MAL protects against fibrosis in NAFLD but not ALD (2008) (1)
Recurrent noctural hypoxaemia is associated with progressive non-alcoholic fatty liver disease (NAFLD) (2008) (1)
O043 : The FNDC5 rs3480 is protective on the steatosis and fibrosis in patients with NAFLD (2015) (1)
Polymorphism in the interleukin (IL-10) gene in patients with inflammatory bowel disease (1998) (1)
The ADAMs: A modular protein family with metalloproteinase and proteoglycan degrading activities expressed by the hepatic stellate cell (2001) (1)
Grading alcoholic hepatitis (2005) (1)
720 Oxidative stress is an independent risk factor for the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis (2003) (1)
What is Non‐Alcoholic Fatty Liver Disease (NAFLD), and Why is it Important? (2013) (1)
1362 CLINICAL BUT NOT HISTOLOGICAL FACTORS PREDICT LONG-TERM PROGNOSIS IN PATIENTS WITH BIOPSY PROVEN ADVANCED ALCOHOLIC LIVER DISEASE (2012) (1)
P87 Vascular Adhesion Protein-1 promotes increases in liver infiltrating CD4+ T cells and NKT cells and induction of fibrogenesis in steatohepatitis (2011) (1)
82 KRUPPEL LIKE FACTOR 6 (KLF6) REGULATES HEAPTIC INSULIN RESISTANCE (HEP-IR) (2010) (1)
1369 HIGH-INTENSITY INTERMITTENT EXERCISE THERAPY REDUCES LIVER FAT AND IMPROVES BODY COMPOSITION IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2013) (1)
Alcohol—Risks and Mechanisms of Damage (1994) (1)
Polymorphism in the interleukin-10 (IL-10) promoter is associated with fibrotic alcoholic liver disease (1998) (1)
Ethanol Metabolism and Pathogenesis of Alcoholic Liver Injury (2008) (1)
GUTJNL216077-225110 1265..1269 (0)
NON-ALCOHOLIC STEATOHEPATITIS. AUTHORS' REPLY (1999) (0)
Non-alcoholic steatohepatitis — therapeutic interventions (2009) (0)
Treatment of NAFLD (2014) (0)
Long-term orlistat treatment reduces endotoxinaemia in fatty liver disease patients (2007) (0)
ResearchElevated endotoxin levels in non-alcoholic fatty liver disease (2015) (0)
CTLA-4 gene polymorphisms are associated with acute rejection after liver transplantation (2005) (0)
Diet, Physical Activity, Sedentary Behaviour and Sleep in 1289 Adults with Liver Disease; A Cross Sectional Study of Data from the UK Biobank (2016) (0)
F.N.39 HOMOZYGOSITY FOR THE PNPLA3/ADIPONUTRIN I148M POLYMORPHISM INFLUENCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2010) (0)
Polymorphisms in the T-cell regulatory gene CTLA-4 are associated with susceptibility for acute rejection after liver transplantation (2006) (0)
29. Non-Alcoholic Fatty Liver Disease (2010) (0)
Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆" [J Hepatol (2020) 505-515]. (2023) (0)
Evidence that alcoholic liver disease is due to immune mechanisms in genetically susceptible drinkers (2002) (0)
The burden of alcoholic liver disease (ALD) on a regional referral centre (2001) (0)
Subject Index Vol. 55, 2009 (2009) (0)
Failure of biliary excretion leads to accumulation of digoxin-like immunoreactive subtances in liver disease (1992) (0)
Non-Alcohlic Fatty Liver Disease is Associated with Recurrent Falls and Significant Injury (2009) (0)
Exercise Therapy in Patients Consuming Moderate Alcohol: A Randomised Control Trial (2016) (0)
BCMO1 deficiency induces nonalcoholic steatohepatitis independent of fatty acid oxidation and synthesis (2011) (0)
Genetic susceptibility to alcoholic liver disease (2004) (0)
Fatigue in NAFLD is severe and associates with excessive daytime somnolence but not with liver disease severity or insulin resistance (2007) (0)
Regulation of human phosphatidate phosphohydrolase in human liver (1991) (0)
Physical activity levels are lower in people with non-alcoholic fatty liver disease than matched healthy controls (2012) (0)
Liver Disease in Obesity (2009) (0)
1290 SULFATASE-2 (SULF2) EXPRESSED IN HEPATOCYTES AND STROMAL CELLS CONTRIBUTES TO THE DEVELOPMENT OF STEATOSIS, THE PROGRESSION OF NAFLD TO FIBROSIS AND THE ADVANCEMENT OF CANCER (2013) (0)
Genetic Factors in the Pathogenesis of Drug-Induced Liver Injury (2013) (0)
Non-Alcoholic Fatty Liver Disease (2018) (0)
Monotherapy with mycophenolate mofetil (MMF): Good for the kidneys badfor the liver (2000) (0)
European liver fibrosis panel of serum markers can predict serious fibrosis on biopsy and clinical outcome in patients with mixed aetiology chronic liver disease (2008) (0)
Identification of phospholipase D gene products in activated rat hepatic stellate cells - Stimulation by PDGF and nucleotides (2001) (0)
Subject Index Vol. 30, Suppl. 1, 2012 (2012) (0)
Comprar Liver Under Constant Attack - From Fat to Viruses | Day, C.P. | 9789048127580 | Springer (2009) (0)
1 GENETIC VARIATION IN LGALS 9 CONFERS SUSCEPTIBILITY TO ALCOHOLIC LIVER DISEASE (2016) (0)
Iron content of alcoholic fatty liver does not predict progression to fibrotic disease (1998) (0)
[704] MITOCHONDRIAL DNA HAPLOGROUPS ASSOCIATED WITH HISTOLOGICAL SEVERITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) (2007) (0)
PWE-286 Direct serum markers are more accurate than simple marker panels for the detection of fibrosis in non-alcoholic fatty liver disease (NAFLD) (2012) (0)
Endothelin induced activation of hepatic stellate cells is via JNK and p38 map kinases (1998) (0)
University of Dundee Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study (0)
Claudin 10 (CLDN10) - a Candidate Suceptibility Gene for NAFLD Progression (2009) (0)
1076 A “loss-of-function” polymorphism in ICAM-1 protects heavy drinkers from alcoholic liver disease (2003) (0)
Neo-antigen specific T-cell responses are closely associated with the presence of liver disease in heavy drinkers (2002) (0)
Relationship of UGT2B7 genotype with diclofenac hepatotoxicity (2003) (0)
1282 MILD STEATOSIS AND IMPAIRED GLUCOSE TOLERANCE ARE ASSOCIATED WITH LIVER CANCER DEVELOPMENT, WHILE PROGRESSION TO NASH INCREASES NUMBER/SIZE IN AN ANIMAL MODEL OF NAFLD (2013) (0)
Sensitivity analysis of the primary outcome (2015) (0)
liver disease clinical outcomes in patients with chronic Enhanced liver fibrosis test can predict and (0)
Genetic Polymorphisms of Galectin-9 (Gal-9) Associated with Risk of Developing Alcoholic Liver Disease (ALD) in Humans (2013) (0)
Bile acids have a direct effect on collagen biosynthesis by hepatic stellate cells (2002) (0)
European liver fibrosis markers can predict clinical outcome in patients with chronic liver disease (2008) (0)
Liver: Can pentoxifylline secure its place in liver therapeutics? (2010) (0)
58 THE KRUPPEL-LIKE FACTOR 6 (KLF6) GENOTYPE WHICH IS ASSOCIATED WITH NAFLD PROGRESSION IS ASSOCIATED WITH HIGHER FASTING SERUM GLUCOSE LEVELS IN HEALTHY INDIVIDUALS (2009) (0)
Genetic evidence that lipid trafficking plays a key role in fibrosis in non alcoholic fatty liver disease (2007) (0)
Autonomic function is impaired across the spectrum of NAFLD (2017) (0)
Immunology and Liver Disease / Liver and Metabolic Syndrome: Immunology and Liver Disease Falk Workshop 2009, Hannover, October 2009 / Liver and Metabolic Syndrome Falk Symposium 171, Hannover, October 2009 (2010) (0)
Cost-Effectiveness of Diagnostic Tests for People At Risk of Non-Alcoholic Fatty Liver Disease (NAFLD) in The UK (2016) (0)
European liver fibrosis (ELF) markers accurately distinguish fibrosis severity in non alcoholic fatty liver disease (NAFLD); An external validation study (2006) (0)
Extrahepatic effects of alcohol: an overview (2002) (0)
Integrin receptor expression changes in diseased hepatic stellate cells (2001) (0)
Increased risk of obstructive sleep apnoea in patients with non-alcoholic fatty liver disease (2012) (0)
[22] THE KLF6 (IVS1-27G > A) POLYMORPHISM IS ASSOCIATED WITH NON-PROGRESSIVE NAFLD (2007) (0)
O065 : Mechanistic study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress (2015) (0)
P1043 : Exercise reduces liver fat, visceral fat and circulating triglycerides, but not circulating inflammatory markers in non-alcoholic steatohepatitis (2015) (0)
Dataset Supplementing The Article A Randomised Controlled Trial Of Losartan As An Anti-Fibrotic Agent In Non-Alcoholic Steatohepatitis (2017) (0)
1076 DIRECT SERUM MARKERS ARE MORE ACCURATE THAN SIMPLE MARKER PANELS FOR THE DETECTION OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) (2012) (0)
[699] DIFFERENTIAL EXPRESSION OF GSTT1 AND GSTT2 IS ASSOCIATED WITH MORE ADVANCED FIBROSIS IN PATIENTS WITH NAFLD (2007) (0)
P09 Validation of a novel biomarker model for the prediction of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease (2011) (0)
Pain as a complication of opiate antagonist therapy in cholestasis: A single centre experience (2002) (0)
Regulation of ADAMS family members in hepatic stellate cells by soluble growth factors: Evidence for their role in hepatic fibrogenesis (2001) (0)
VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2011) (0)
Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282]. (2022) (0)
1337 CARDIAC FUNCTION IMPROVES FOLLOWING HIGH INTENSITY INTERMITTENT EXERCISE THERAPY IN NON-ALCOHOLIC FATTY LIVER DISEASE (2013) (0)
Unit cost: intervention, initial admission and adverse events costs (2015) (0)
Liver fat independently associates with impaired cardiac and autonomic function (2019) (0)
Enhanced liver fibrosis (ELF) score predicts clinical outcome in patients with chronic liver disease (2008) (0)
1338 NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH HIGHER OBJECTIVELY MEASURED SEDENTARY BEHAVIOUR AND LOWER LEVELS OF PHYSICAL ACTIVITY THAN MATCHED HEALTHY CONTROLS (2013) (0)
A polymorphism in CTLA-4 is associated with the presence of anti-CYP2E1 antibody titres in patients with alcoholic liver disease (2001) (0)
Fatigue in non-alcoholic fatty liver disease: is there a role for hypothyroidism Response (2009) (0)
Unsupervised high-intensity intermittent training reduces liver fat and improves body composition in adults with non-alcoholic fatty liver disease (NAFLD) (2013) (0)
Terlipressin for hepatorenal impairment in alcoholic hepatitis (2000) (0)
Allo- and auto-antibody responses in ALD as biomarkers of prognosis (2010) (0)
Promoter polymorphisms of IL-10 and IL-4 predict risk ofdiclofenac-induced hepatitis (2000) (0)
1001 CYTOCHOME P450 2E1 (CYP2E1) AUTOREACTIVITY IN ALCOHOLIC LIVER DISEASE: NO EVIDENCE FOR A PATHOGENETIC ROLE (2009) (0)
Mitochondrial DNA haplogrouping in non alcoholic fatty liver disease (NAFLD) (2006) (0)
Health-economic evaluation (2016) (0)
Subject Index Vol. 34, Suppl. 1, 2016 (2016) (0)
TNF and HLA DR8 Polymorphisms in Primary Biliary Cirrhosis: Genetic Control of Disease Progression? (1998) (0)
OPINION Nonalcoholic fatty liver disease: new treatments (2015) (0)
Polymorphisms of immunoregulatory genes: A step towards individually tailored immunosuppression? (2001) (0)
Interleukin-10 -592 promoter polymorphism and primary biliary cirrhosis: No association with disease susceptibility or severity (1998) (0)
A polymorphism in interleukin-4 is associated with Crohn's disease (2000) (0)
Genetic Predisposition to NAFLD and NASH: Implications for Pathogenesis, Diagnosis, Prevention, and Management (2013) (0)
1308 THE FIB-4 SCORE RELIABLY EXCLUDES ADVANCED FIBROSIS IN A DIABETIC COHORT WITH NAFLD (2012) (0)
Chapter 28 – Alcoholic Liver Disease (2012) (0)
P13 Allo- and auto-antibody responses in alcoholic liver disease as biomarkers of prognosis (2010) (0)
Title : Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study (2016) (0)
P0271 : Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease (2015) (0)
Contents Index Vol. 55, 2009 (2009) (0)
Digoxin-like factors in liver disease. (1989) (0)
73 KR ÜPPEL LIKE FACTOR 6 (KLF6) PROTECTS FROM NAFLD PROGRESSION THROUGH REGULATION OF ADIPOSE TISSUE INSULIN RESISTANCE (2013) (0)
Warfarin induced cholestatic jaundice in a patient receiving total parenteral nutrition (2008) (0)
Average adverse event investigations per treatment arm (2015) (0)
Nucleotides stimulate phospholipasc D activity in hepatic stellate cells: evidence for the involvement of a single nucleotide receptor, protein kinase C and a pertussis toxin insensitive guanine-nucleotide binding protein (2000) (0)
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group (2014) (0)
Role of oxidative stress in promoting immune reactions associated with alcoholic liver disease (2004) (0)
Circulating visfatin levels reduced in patients with non-alcoholic fatty liver disease irrespective of type 2 diabetes mellitus status (2009) (0)
Mo1001 Prognostic Relevance of Serum Ferritin in Patients With Nonalcoholic Fatty Liver Disease (2013) (0)
[719] EFFECTS OF ETHANOL ON ENDOTOXIN-MEDIATED CYTOKINE RELEASE: SENSITISATION VIA TLR4 BUT NORMAL TOLERANCE (2007) (0)
Anti-cytochrome P4502E1 autoantibody titre associates with immune liver histology in advanced alcoholic liver disease (2004) (0)
Ethanol-induced histone acetylation: A novel mechanism for enhancement of inflammation in alcoholic hepatitis? (2007) (0)
Susceptibility to alcoholic liver disease is determined by genetically determined differences in the immune response to acetaldehyde adducts (2000) (0)
Mitogenic Signal Transduction Pathways Involved in Hepatic Stellate Cells (1996) (0)
A common polymorphism in the ABCB11 gene encoding for the bile salt export pump is associated with advanced fibrosis in hepatitis C infection but not in fatty liver disease (2010) (0)
Non-alcoholic steatohepatitis: metabolic syndrome of the liver (2008) (0)
British Association for the Study of the Liver Meeting (2000) (0)
Prognostic score formula (2015) (0)
1308 A ROLE FOR DNA REPAIR PROTEIN KINASE (DNA-PK) IN THE PROGRESSION OF SIMPLE STEATOSIS TO STEATOHEPATITIS (NASH)? (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christopher Paul Day?

Christopher Paul Day is affiliated with the following schools:

Newcastle University